PeerConnect


photo

Deborah Toscano - Analyst Profile

Senior Industry Analyst
Frost & Sullivan
Healthcare

Summary

Functional Expertise

Over 20 years of life sciences industry expertise, which include pharmaceutical research and consulting. Particular expertise in:
  • Analysis and interpretation of scientific data
  • Preparation of high quality executive-ready deliverables with strong attention to technical detail

Industry Expertise

Experience base covering broad range of sectors, leveraging long-standing working relationships with leading industry participants

  • Diabetes and metabolic diseases
  • Cardiovascular diseases
  • Preclinical animal modeling and pharmacology

What I bring to the Team

  • Therapeutic area expertise, particularly diabetes/metabolic diseases and cardiovascular diseases gained from 20+ years in pharmaceutical R&D
  • Inside knowledge of “Big Pharma” research and drug development
  • Knowledge of the clinical research environment
  • Strong analytical and interpretive capabilities

Career Highlights

  • Extensive expertise in research and development of diabetes and cardiovascular drugs. Nearly 20 years of preclinical research experience at Novartis Pharmaceuticals
  • Author or co-author of several publications in peer-reviewed scientific journals

Education

B.S. in Biology from Delaware Valley College, Doylestown, PA
Graduate studies in Biology, Seton Hall University, South Orange, New Jersey
Master’s Certificate in Clinical Trials Management from Thomas Edison State College, Trenton, New Jersey

Areas of expertise
MARKET RESEARCH
COMPETITIVE INTELLIGENCE


Recent items from Deborah Toscano

Attractive Market Lures Hundreds of Innovators, Large and Small
Breakthroughs in drug discovery have led to rich and competitive pipelines for rare diseases such as rare cancers as well as neurologic disorders and musculoskeletal disorders, among many other therapeutic areas. This research service provides a comprehensive global overview and analysis of global orphan drugs development, with an emphasis on the US market. Included are market background and global overview and analysis of drug development and regulatory activity by disease area and geography, detailed product and pipeline analysis of orphan drugs by therapeutic area and disease, and company analysis, including activity analysis and key companies to watch.
Published: Feb 27 2014 Competitive Pipeline Analysis
An Addendum to "Specialty Physicians Discuss their Opinions of the United States Biosimilars Market"
Frost & Sullivan assessed physicians’ willingness to prescribe biosimilars in the United States. The objective of this research was to conduct a highly qualitative analysis of a representative sample of 20 preselected practicing specialty physicians in the United States in the spirit of an interactive roundtable discussion. The primary goal was to encourage participants to freely express opinions and ideas around all aspects of a topic, facilitating a free exchange about how biosimilars will impact their practice and the overall US healthcare market. The biosimilar research panel was conducted over a three-day period (October 11-13, 2011). Questions and discussions were designed to gauge both short-term and long-term trends and impacts.
Published: Feb 21 2014 Market Insights
Improvements in Administration and Efficacy Drive Growth
Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as the base year. Segmentation by disorder is provided. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.
Published: Dec 11 2013 Market Research
Published: Oct 18 2013 Best Practices
This issue of Vital Signs, released on September 30, 2013, provides a market overview and drug pipeline analysis of Type 2 diabetes therapeutics. Additionally, a company spotlight is provided for Trovagene in San Diego, CA. The company has a proprietary transrenal nucleic acid platform with the potential to deliver superior molecular diagnostics in urine.
Published: Sep 30 2013 Market Insights
The FDA has been on a roll with new guidance for industry, this time for an area in dire need of innovation and drug development activity – serious bacterial infections.  The GAIN act (Generating Antibiotic Incentives Now) which was signed into law in July of 2012 authorized a streamlined development process for antibacterial drugs meeting certain...
27 Sep 2013 Blog post
Market Opportunities for Differentiated Therapeutics
Type 2 diabetes is one of the most significant global health concerns of modern times. The size of the diabetes therapeutics market has stimulated a vast and growing pipeline of potential new therapies aimed at the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients. This research service evaluates the global market for the pharmaceutical management of type 2 diabetes from 2009 to 2017, with 2012 as the base year. Segmentation by drug type (insulin and non-insulin therapeutics) and regional breakdown are provided. Included are products available in the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.
Published: Sep 23 2013 Market Research
Published: Aug 12 2013 Best Practices
The FDA hosted a live webinar this morning to present the new draft guidance for industry for fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation. This is the first such guidance published by the FDA on the new Breakthrough Therapy Designation and Accelerated Approval. The intent of these...
05 Aug 2013 Blog post
This morning, the FDA held a webinar to discuss and summarize the revised draft guidance for industry for development of drugs for rheumatoid arthritis. Since the last guidance document published back in 1999, a lot has happened in the way of medical advancements, the agency felt the time was right to update their recommendations for industry to ac...
25 Jul 2013 Blog post
Teva and Lonza have just announced the termination of their joint venture to co-develop biosimilars, upon the realization that the development costs and time to market were beyond initial estimations. The agreement was formed in 2009. When biosimilars were first a hot topic, it was a common perception that the scenario would be similar to producing...
25 Jul 2013 Blog post
Roche announced yesterday that they have terminated all trials of aleglitazar, a dual PPAR alpha/gamma agonist in Phase 3 for diabetes management as well as cardiovascular risk reduction in diabetes patients.  All ongoing trials were discontinued due to safety concerns that arose in AleCardio, the trial assessing the potential benefit of the drug i...
11 Jul 2013 Blog post
MedChemica, a UK consulting company specializing in medicinal chemistry, recently announced an agreement between Roche/Genentech and AstraZeneca to share details of their respective drug molecular designs and some relevant experimental results, with MedChemica acting as the third party to analyze the data using Matched Molecular Pair analysis.   Th...
02 Jul 2013 Blog post
Earlier this month, a joint meeting of the FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) was held to re-visit the cardiovascular risk profile of Avandia (rosiglitazone). This high profile meeting was held to discuss the readjudication of the Rosiglitazone Evaluated f...
25 Jun 2013 Blog post
Published: May 30 2013 Best Practices
In a surprising announcement made yesterday, Merck and Pfizer are teaming up to commercialize Pfizer’s SGLT2 inhibitor ertugliflozin for diabetes.  This announcement took the pharma world by surprise, especially since Merck in particular is not known for forming partnerships with other big pharmas.  Typically these partnerships leverage the individ...
30 Apr 2013 Blog post
Published: Apr 29 2013 Best Practices
Persistent Unmet Need Fuels Antiviral Drug Development for Bloodborne Pathogens
This research service focuses on antiviral/antiretroviral therapeutics for the treatment of infection with blood-borne pathogens of current global interest, specifically viral hepatitis and HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HBV, HCV, and HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
Published: Mar 26 2013 Market Insights
In follow up to my last blog, as a result of the Omontys recall, Affymax has resorted to a 75 percent reduction in staff in order to stay afloat, and may even be forced into bankruptcy. Although Affymax is a small company who is reliant on this single product, they were forecast to earn peek sales from Omontys in 2018 of approximately $484 million...
21 Mar 2013 Blog post
Affymax’s and Takeda’s biologic drug for anemia, Omontys, is the latest victim of the discovery of serious adverse events in the post-marketing setting. Less than a year after the FDA granted marketing approval, reports of serious anaphylactic reactions, three of which were fatal, prompted the companies to recall the drug. Omontys is a similar drug...
25 Feb 2013 Blog post

Deborah's Tweets

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..